Sagility India Limited is a niche healthcare-focused technology and business process outsourcing (BPO) company that provides end-to-end services to U.S.-based healthcare payers and providers. Formerly known as Berkmeer India Private Limited, the company was rebranded as Sagility in 2021 and listed on Indian stock exchanges in 2023. Headquartered in Bengaluru, it specializes in claims processing, revenue cycle management (RCM), payment integrity, and clinical solutions for American health insurers and hospitals. As of January 2026, Sagility is delivering explosive profit growth—273% YoY—driven by strong client retention and U.S. healthcare outsourcing tailwinds. However, it trades at a premium valuation with low return ratios, making it a high-risk, high-reward bet. This article provides a data-driven outlook on the Sagility share price target 2026–2030.
Sagility India: Company Overview
- Founded: 2021 (as a demerged entity; operational since 2015 under Alight Solutions)
- Managing Director: Mr. Ramesh Kailasam
- NSE Symbol: SAGILITY
- Core Segments:
- Healthcare Payer Services (65%) – claims, payment integrity, care management
- Provider Services (35%) – revenue cycle management for hospitals
- Market Position: Holds ~1.23% of the U.S. healthcare BPO market; serves top-tier U.S. insurers
Sagility benefits from long-term contracts, high client stickiness, and rising U.S. healthcare complexity—making it a strategic play on global healthcare digitization.
Sagility India: Key Financial Snapshot
| Metric | Value |
|---|---|
| Current Share Price | ₹52.08 |
| Market Capitalization | ₹24,361.63 Cr |
| No. of Shares Outstanding | 468.13 Cr |
| P/E Ratio (TTM) | 60.99 |
| P/B Ratio | 2.35 |
| EPS (TTM) | ₹0.85 |
| Book Value (TTM) | ₹22.13 |
| ROE | 2.89% |
| ROCE | 4.47% |
| Dividend Yield | 0.00% |
| Face Value | ₹10 |
| Cash | ₹89.94 Cr |
| Debt | ₹802.04 Cr |
| Promoter Holding | 50.95% |
| Sales Growth (YoY) | 14.86% |
| Profit Growth (YoY) | 273.38% |
Note on Profit Growth: The 273% YoY jump stems from operational leverage and cost rationalization post-listing. However, ROE remains critically low at 2.89%, indicating poor capital efficiency.
Sagility Share Price Target Forecast (2026–2030)
| Year | Target Price Range (₹) |
|---|---|
| 2026 | ₹58 – ₹68 |
| 2027 | ₹65 – ₹78 |
| 2028 | ₹72 – ₹90 |
| 2029 | ₹80 – ₹105 |
| 2030 | ₹88 – ₹120 |
Sagility Share Price Target 2026
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2026 | ₹58 | ₹68 |
Sagility reported 273% YoY profit growth in FY2025, driven by U.S. client expansion and margin improvement. Despite this, its ROE of just 2.89% and high P/E of 60.99x reflect speculative valuation. The 2026 target range assumes continued client wins and no major attrition in the U.S. healthcare sector.
Sagility Share Price Target 2027
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2027 | ₹65 | ₹78 |
If the company sustains 20–25% earnings growth and improves asset turns, EPS could reach ₹1.00–₹1.15 by FY27. Assuming a P/E of 60–65x, the 2027 target range is justified—but remains speculative.
Sagility Share Price Target 2028
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2028 | ₹72 | ₹90 |
By 2028, benefits from AI-driven automation in claims processing and cross-selling should reflect in margins. A P/E of 62–68x on projected EPS of ₹1.10–₹1.30 supports the ₹72–₹90 band.
Sagility Share Price Target 2029
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2029 | ₹80 | ₹105 |
Long-term tailwinds include rising U.S. healthcare spending ($5 trillion+ by 2030) and regulatory complexity driving outsourcing. If competition doesn’t erode pricing, EPS could reach ₹1.30–₹1.50 by FY29. At a P/E of 65–70x, the 2029 target is ₹80–₹105.
Sagility Share Price Target 2030
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2030 | ₹88 | ₹120 |
Over a five-year horizon, Sagility remains a high-growth, low-return outsourcing play. A terminal P/E of 70–75x on FY30 EPS (~₹1.40–₹1.60) justifies the ₹88–₹120 range.
Sagility India: Shareholding Pattern
| Category | Holding (%) |
|---|---|
| Promoters | 50.95% |
| Domestic Institutional Investors (DII) | 21.36% |
| Public & Retail | 17.44% |
| Foreign Institutional Investors (FII) | 10.25% |
High promoter holding ensures strategic continuity. Strong DII interest reflects confidence in U.S. revenue visibility.
Sagility India: Strengths vs Risks
Strengths:
- Exclusive focus on high-margin U.S. healthcare BPO
- Long-term contracts with Fortune 500 clients
- Explosive profit growth (273% YoY)
- Debt reduced post-IPO (Debt/Equity: ~0.4x)
Risks:
- Extremely low ROE (2.89%) limits capital efficiency
- 100% revenue dependence on U.S. healthcare policy
- No dividend payout (0% yield)
- Contingent liabilities of ₹1,200 Cr require monitoring
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | High |
| Ideal Time Horizon | 5+ years |
| Volatility | Very High (newly listed, low float) |
| Dividend/Income Potential | None (0% yield) |
| Best For | Aggressive investors betting on U.S. healthcare outsourcing boom |
- Healthcare analytics
- Artificial intelligence–driven solutions
- Value-based care support services
Final Verdict
Sagility India is a high-potential but capital-inefficient player in a niche global market. While not a compounder like IT majors, its strategic positioning offers optionality.
Our Sagility share price target 2026–2030 (₹58 to ₹120) reflects cautious optimism—rooted in client visibility but tempered by execution risk. Upside is substantial if U.S. demand accelerates; downside is steep due to low ROE and single-market dependence.
Disclaimer: Price targets are estimates based on publicly available data and sector analysis. They are not investment advice. Consult a SEBI-registered advisor before making decisions.
Sources
- Screener.in – Sagility Consolidated Page (FY2025 + TTM)
- Finology Ticker – SAGILITY Financials & Analysis
- Groww.in – Sagility Stock Profile
- Company Investor Presentation (Q3 FY26, Jan 2026)
- U.S. Centers for Medicare & Medicaid Services (CMS) – National Health Expenditure Projections 2025
